Intellia Therapeutics Inc
Suletud
SektorTervishoid
11.73 -1.59
Ülevaade
Aktsiahinna muutus
24h
Min
11.68
Max
12.17
Sissetulek | -107M -203M |
|---|---|
Müük | -7.4M 7.7M |
Aktsiakasum | -0.8 |
Kasumimarginaal | -2,648.714 |
Töötajad | 377 |
EBITDA | -11M -105M |
Järgmine tulemuste avaldamine | 4. nov 2026 |
|---|
Turukapital | 280M 1.8B |
|---|---|
Eelmine avamishind | 13.32 |
Eelmine sulgemishind | 11.73 |
Uudiste sentiment
By Acuity
34%
66%
77 / 339 Pingereas Healthcare
Intellia Therapeutics Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Intellia Therapeutics Inc Prognoos
Sentiment
By Acuity
77 / 339 Pingereas Tervishoid
Uudiste sentiment
Languse märgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.